CRVS today
$11.47+$0.10 (+0.88%)close Nov 11, 2026Trend
DailyDowntrend (starting)
4 hourStrong Bullish
1 hourStrong Bullish
15 minSymmetric Triangle
5 minSymmetric Triangle
Daily trend turns up above $22.14
Key levels
Resistance$13.06
Resistance$11.65
Support$9.63
Support$8.27
Latest news & SEC filings
EarningsCorvus Pharmaceuticals Posts Q3 2026 Results
EarningsCorvus Pharma holds Q3 2026 earnings call
ProductCorvus sets March 2027 for Angel Pharma's first China skin-disease results
All CRVS news →About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company that develops drugs targeting proteins involved in immune cell function. Its lead candidate, soquelitinib, is an oral ITK inhibitor being tested in T cell lymphoma and atopic dermatitis, with two other candidates, ciforadenant and mupadolimab, in development for solid tumors. The company operates in the United States and relies on third parties to manufacture its product candidates.
Based on the company's 10-K filed Mar 12, 2026.
Nasdaq · Healthcare
Corvus Pharmaceuticals, Inc. (CRVS)
What Is the Price Target for CRVS?
SEPT Low Target
$40.00
SEPT Mid Target
$40.00
SEPT High Target
$40.00
Analyst Consensus
$40.00
Is CRVS a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CRVS.
Start Free Trial →Is CRVS Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$31.59
12
Moat Score
NONE
3/9
Piotroski Score
38.1
Altman Z-Score
What Is Smart Money Doing with CRVS?
Insider Signal
NEUTRAL
3 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Moore David Scott | director | Buy | 21,700 | $250K | Jun 11, 2026 |
| MILLER RICHARD A MD | director officer | Buy | 5,000 | $60K | May 18, 2026 |
| MILLER RICHARD A MD | director officer | Buy | 1,932 | $23K | May 18, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →CRVS Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
48.04%
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for CRVS
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for CRVS, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:06 | $11.47 | 4,156 | $$48K | SELL |
| 21:00:06 | $11.47 | 1,011 | $$12K | SELL |
| 21:00:00 | $11.47 | 1,100 | $$13K | SELL |
| 21:00:00 | $11.47 | 1,500 | $$17K | BUY |
| 20:57:41 | $11.51 | 1,400 | $$16K | MIDPOINT |
5 dark pool trades shown · $$105K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for CRVS
PREVIEWSEPT Investing provides real-time options flow tracking for CRVS, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $15 | Jan 21 | 436 | $$2675 | 5 | SWEEP |
| CALL | $30 | Jan 21 | 436 | $$574 | 2 | SWEEP |
| CALL | $15 | Jan 21 | 436 | $$1060 | 2 | SWEEP |
| CALL | $30 | Jan 21 | 436 | $$294 | 1 | SWEEP |
| CALL | $15 | Jan 21 | 436 | $$537 | 1 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
What Traders Are Saying About CRVS
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for CRVS. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
SEPT Brain on $CRVS -- Neutral Bounced back with 91% buying after prior session selling. Uptrend holds while above $11.44. $12 psychological level is the next resistance to watch. The Play: Watch fo...
Join 3,500+ traders discussing CRVS in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Corvus Pharmaceuticals, Inc. (CRVS) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CRVS — frequently asked questions
What is CRVS stock price today?
Corvus Pharmaceuticals, Inc. (CRVS) is at $11.47, up 0.88% (+$0.10) at the Nov 11, 2026 close.
Why is CRVS stock moving today?
Latest CRVS news — Nov 5, 2026: Corvus Pharmaceuticals Posts Q3 2026 Results · Nov 5, 2026: Corvus Pharma holds Q3 2026 earnings call
What is the CRVS price target?
The average analyst price target for CRVS is $40.00, ranging from $40 to $40, based on 1 analysts. Latest: Goldman Sachs initiates on Apr 17, 2026.
What do analysts rate CRVS?
Analyst ratings for CRVS: 0 Buy, 1 Hold, 0 Sell — consensus Hold.
Did CRVS beat earnings?
CRVS last reported on Aug 6, 2026: EPS -$0.19 vs -$0.16 expected — a miss of 19.4%.
Does CRVS pay a dividend?
CRVS does not currently pay a dividend.
What are CRVS support and resistance levels?
Support: $9.63, $8.27. Resistance: $11.65, $13.06, $14.34.
What are insiders doing with CRVS?
Insider activity: NEUTRAL, 3 buys and 0 sells in the last 90 days.
What is the latest news on CRVS?
Nov 5, 2026: Corvus Pharmaceuticals Posts Q3 2026 Results · Nov 5, 2026: Corvus Pharma holds Q3 2026 earnings call · Nov 5, 2026: Corvus sets March 2027 for Angel Pharma's first China skin-disease results